University of Kansas Cancer Center - CRC
Welcome,         Profile    Billing    Logout  
 22 Trials 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Baranda, Joaquina C
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
NCT05327010: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Recruiting
2
88
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
08/25
08/25
NCT05691491: Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Recruiting
1/2
58
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Tuvusertib, ATR Kinase Inhibitor M1774, M 1774, M-1774, M1774
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
01/25
01/25
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi, Sanofi Aventis Recherche & Développement
Solid Tumor
01/27
09/28
NCT03982212: A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Active, not recruiting
1
10
US
Copaxone, Glatiramer acetate, Glatopa
University of Kansas Medical Center
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
12/22
07/24
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

Recruiting
1
350
US, RoW
IMP7068
Impact Therapeutics, Inc., Covance
Advanced Solid Tumors
04/23
08/23
NCT04412616: ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies

Recruiting
1
60
US, RoW
ZZ06
Changchun Intellicrown Pharmaceutical Co. LTD, Covance
Advanced EGFR Positive Solid Tumor
12/23
04/24
NCT04222413: Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Recruiting
1
98
US
Metarrestin
National Cancer Institute (NCI)
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
12/26
12/27
ETCTN 10402, NCT04514497: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Active, not recruiting
1
96
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
02/25
02/25
NCT03560882: A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Active, not recruiting
1
50
US
Atorvastatin
Joaquina Baranda
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
10/22
08/25
AIM-NIVO, NCT03816345: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Recruiting
1
300
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
08/26
08/26
Khan, Qamar
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT00921115: Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Completed
2
42
US
Fulvestrant, Faslodex, Anastrazole, Arimidex
University of Kansas Medical Center, AstraZeneca
Invasive Breast Cancer
04/15
03/23
FELINE, NCT02712723: Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Active, not recruiting
2
121
US
Letrozole, Femara, CGS 20267, LTZ, Ribociclib, LEE011, LEE-011, Placebo
Qamar Khan, Novartis Pharmaceuticals
Breast Cancer
08/18
04/23
HERMET, NCT03238495: Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer

Recruiting
2
100
US
Taxotere, Carboplatin, Herceptin + Pertuzumab, Metformin
Qamar Khan
HER2-positive Breast Cancer
06/22
06/23
X7-7, NCT02595320: Capecitabine in Metastatic Breast and GI Cancers

Active, not recruiting
2
200
US
Capecitabine, Xeloda®
Qamar Khan
Breast Cancer, Gastrointestinal Cancer
12/22
12/23
NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Recruiting
1/2
152
US
Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab
Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
05/32
05/32
NCT04606342: ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting
1/2
150
US
ATI-450, Paclitaxel, Capecitabine, Antiresorptive Agents
Washington University School of Medicine, Aclaris Therapeutics, Inc., United States Department of Defense
Breast Cancer, Cancer of Breast
05/25
04/28
NCT05330936: Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment

Completed
1
90
RoW
Potent topical steroid
Pak Emirates Military Hospital
Plaque Psoriasis
09/22
09/22
NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn
1
36
NA
ATI-2231
Washington University School of Medicine, Aclaris Therapeutics, Inc.
Advanced Solid Tumor, Advanced Solid Tumor Malignancies
06/25
06/25
CANINE, NCT04821570: To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment

Active, not recruiting
N/A
500
US
COVID-19 Vaccine
University of Kansas Medical Center
Breast Cancer, Lung Cancer, Melanoma (Skin)
03/24
03/25
Hepler, Kerry
BP1001-201-AML, NCT02781883: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Recruiting
2a
108
US
BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia (AML)
12/24
12/24
NIRA-PANC, NCT03553004: Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (): a Phase 2 Trial

Active, not recruiting
2
18
US
Niraparib Treatment
University of Kansas Medical Center, Tesaro, Inc.
Pancreatic Cancer
04/23
02/25
NCT03321188: Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

Recruiting
2
20
US
HIPEC, Carboplatin, Paclitaxel
Andrea Jewell, University of Kansas Medical Center
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
12/23
12/24
NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Active, not recruiting
2
40
US
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
University of Kansas Medical Center, Merck Sharp & Dohme LLC
Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
04/24
04/25
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

Active, not recruiting
2
24
US
TG01 Vaccine, QS-21, Balstilimab
University of Kansas Medical Center, Targovax ASA
Pancreas Cancer
12/24
12/25
Naviagation, KUCC
NCT03982212: A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Active, not recruiting
1
10
US
Copaxone, Glatiramer acetate, Glatopa
University of Kansas Medical Center
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
12/22
07/24
Navigation, KUCC
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
NCT03762161: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Recruiting
2
22
US
TAS 102
Rahul Parikh, Taiho Oncology, Inc.
Bladder Cancer
07/23
01/24
NCT04992780: Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Recruiting
2
50
US
Hypo-Fractionation, Standard-Fractionation
University of Kansas Medical Center
Non Small Cell Lung Cancer Stage
10/25
11/26
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

Active, not recruiting
2
24
US
TG01 Vaccine, QS-21, Balstilimab
University of Kansas Medical Center, Targovax ASA
Pancreas Cancer
12/24
12/25
NCT06493370: Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

Not yet recruiting
2
48
US
Intravenous ascorbic acid/vitamin C
University of Kansas Medical Center
Bladder Cancer
12/28
12/30
CENDIFOX, NCT05121038: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

Active, not recruiting
1/2
50
US
CEND-1, LSTA1, Certepetide, Panitumumab, Folfirinox, Oxaliplatin,Leucovorin,Irinotecan,Fluorouracil
Anup Kasi, Cend Therapeutics Inc.
Colon Cancer, Pancreas Cancer, Digestive Cancer
09/25
09/26
NCT04781192: The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Recruiting
1/2
40
US
Durvalumab, Regorafenib
University of Kansas Medical Center
Advanced Biliary Tract Cancer
11/25
12/25
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
NCT04467723: Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Recruiting
1/2
25
US
Atezolizumab, Pirfenidone
University of Kansas Medical Center, parkview cancer institute
NSCLC Stage IV, NSCLC, Recurrent
04/24
08/27
NCT03982212: A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Active, not recruiting
1
10
US
Copaxone, Glatiramer acetate, Glatopa
University of Kansas Medical Center
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
12/22
07/24
NCT03560882: A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Active, not recruiting
1
50
US
Atorvastatin
Joaquina Baranda
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
10/22
08/25
NCT04636775: Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

Recruiting
N/A
46
US
Microbiome
Jun Zhang, MD, PhD
NSCLC Stage IV, NSCLC, Recurrent
08/24
12/24
CANINE, NCT04821570: To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment

Active, not recruiting
N/A
500
US
COVID-19 Vaccine
University of Kansas Medical Center
Breast Cancer, Lung Cancer, Melanoma (Skin)
03/24
03/25

Download Options